Breaking News Instant updates and real-time market news.

CSCO

Cisco

$42.09

0.86 (2.09%)

, TEVA

Teva

$20.93

1.6 (8.28%)

12:21
02/15/18
02/15
12:21
02/15/18
12:21

On The Fly: Top stock stories at midday

Stocks opened sharply higher, ignoring the slightly hotter than expected producer inflation data. The market saw its highs in the opening hour, but the averages had given up all their gains during the next few hours of trading and moved into negative ground. Before the losses became to big, the market reversed and moved back into the green, with the Nasdaq leading again so far. ECONOMIC EVENTS: In the U.S., the Producer Price Index rose 0.4% in January on both the headline and the core, which was a little hotter than expected. Initial jobless claims rose 7,000 to 230,000 in the week ended February 10. Industrial production fell 0.1% in January with capacity at 77.5%, which missed expectations. The Philadelphia Fed manufacturing index rose 3.6 points to 25.8 in February. The NAHB housing market index was unchanged at 72 in February. COMPANY NEWS: Shares of Cisco (CSCO) advanced 3% after reporting a Q2 beat on earnings and gross margins along with a higher than expected outlook for Q3 revenue growth. Cisco also raised its dividend 14% and approved a $25B increase to its stock buyback program... Teva (TEVA) shares are more than 8% higher at midday after Warren Buffett's Berkshire Hathaway (BRK.A) disclosed in an SEC filing last night that it purchased 18.9M shares of the pharmaceutical company's stock during Q4 of 2017... A. Schulman (SHLM) is up nearly 11% to $42.75 per share after LyondellBasell (LYB) revealed it has struck a deal to buy the company for a total consideration of $2.25B. LyondellBasell shareholders will receive $42 per share in cash and one contingent value right per share related to an opportunity to receive certain net proceeds, if any are recovered, from certain ongoing litigation and government investigations relating to A. Schulman's Citadel and Lucent acquisitions. MAJOR MOVERS: Among the noteworthy gainers was Amag Pharmaceuticals (AMAG), which jumped 33% after it and Antares Pharma (ATRS) announced FDA approval for their supplemental New Drug Application for the Makena subcutaneous auto injector drug-device combination product. Also higher after reporting quarterly earnings were SolarEdge (SEDG), TripAdvisor (TRIP), and Aaron's (AAN). Among the notable losers was Alcoa (AA), which slipped 3% after a filing showed that Elliott Management has decreased its stake in the aluminum producer. Also lower after reporting quarterly results were TreeHouse (THS), NetApp (NTAP), and Marathon Oil (MRO). INDEXES: Near midday, the Dow was up 90.52, or 0.36%, to 24,984.01, the Nasdaq was up 54.60, or 0.76%, to 7,198.22, and the S&P 500 was up 12.41, or 0.46%, to 2,711.04.

CSCO

Cisco

$42.09

0.86 (2.09%)

TEVA

Teva

$20.93

1.6 (8.28%)

BRK.A

Berkshire Hathaway

$302,750.00

1745 (0.58%)

AMAG

Amag Pharmaceuticals

$13.90

0.2 (1.46%)

ATRS

Antares Pharma

$1.98

-0.03 (-1.49%)

SEDG

SolarEdge

$36.90

0.9 (2.50%)

TRIP

TripAdvisor

$40.72

0.84 (2.11%)

AAN

Aaron's

$46.31

5.98 (14.83%)

AA

Alcoa

$46.95

-1.59 (-3.28%)

THS

TreeHouse

$37.04

-5.97 (-13.88%)

NTAP

NetApp

$60.64

1.9 (3.23%)

MRO

Marathon Oil

$15.75

-1.2 (-7.08%)

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 06

    Mar

  • 14

    Mar

  • 29

    Mar

CSCO Cisco
$42.09

0.86 (2.09%)

02/15/18
RBCM
02/15/18
NO CHANGE
Target $50
RBCM
Outperform
Cisco price target raised to $50 from $44 at RBC Capital
RBC Capital analyst Mitch Steves raised his price target on Cisco to $50 after a Q2 beat on earnings and gross margins along with much higher than expected outlook for Q3 revenue growth. Steves believes the stock has more room to run, particularly given that Q3 should have the most difficult comparisons for growth in switching. The analyst also believes that the increase in stock buyback and dividend will attract more defensively-minded investors, keeping his Outperform rating.
02/15/18
JEFF
02/15/18
NO CHANGE
Target $48
JEFF
Buy
Cisco shares should continue to re-rate higher, says Jefferies
Jefferies analyst George Notter believes shares of Cisco Systems should continue to re-rate higher, "even from here." Last night's results, guidance, and the narrative around the business were "excellent," Notter tells investors in a pos-earnings research note. He raised his price target for the shares to $48 from $40 and continues to like the risk/reward at current levels. The analyst keeps a Buy rating on Cisco.
02/15/18
COWN
02/15/18
NO CHANGE
Target $51
COWN
Outperform
Cisco price target raised to $51 from $42 at Cowen
Cowen analyst Paul Silverstein raised his price target on Cisco to $51 from $42 as the Q2 results reinforced his investment thesis. He said the return to growth has arrived and was broad-based. Silverstein, who also called the company's stock buyback and increased dividend impressive, reiterated his Outperform rating on Cisco shares.
02/15/18
MKMP
02/15/18
NO CHANGE
Target $48
MKMP
Neutral
Cisco price target raised to $48 from $38 at MKM Partners
MKM Partners analyst Michael Genovese raised his price target on Cisco to $48 after its Q2 results, saying the company posted a clean beat with growth in all major reporting segments, including infrastructure. Genovese points to product order growth of 5%, up from 1% in the prior quarter, allowing for Q3 revenue growth outlook of 3%-5% that's above his view of 1.5%. The analyst keeps his Neutral rating on Cisco despite the good quarter, noting "weak secular Routing trends in the Service Provider market" and soft performance in "more sophisticated large Enterprise customer".
TEVA Teva
$20.93

1.6 (8.28%)

02/13/18
WELS
02/13/18
NO CHANGE
WELS
Teva generic comes earlier than expected, says Wells Fargo
Wells Fargo analyst David Maris says Momenta Pharmaceuticals' (MNTA) generic approval of Teva Pharmaceutical's (TEVA) Copaxone came earlier than expected. As recently as the Q4 conference call on February 8, Teva management expected that another generic Copaxone approval would not come until April 2018, Maris tells investors in a research note. The analyst's forecasts assume a continued erosion of Copaxone sales, with sales of $700M in Q1, $500M sales in Q2 and $400M in Q3 and Q4. Maris keeps an Underperform rating on Teva.
02/12/18
02/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nasdaq (NDAQ) upgraded to Outperform from Market Perform at Wells Fargo by analyst Christopher Harris, who said the company is at an inflection point where both its trading and non-trading segments will begin to generate faster growth. He sees a "pathway to much higher profit margin" over the next two years and believes the stock is "relatively inexpensive" at a discount to the S&P 500 Index. 2. Teva (TEVA) upgraded to Outperform from Neutral at Credit Suisse by analyst Vamil Divan. The analyst sees "early execution" towards the company's restructuring plan and believes its 2018 outlook is achievable. He feels expectations are now reasonable believes the upside path is now clearer. 3. Cisco Systems (CSCO) upgraded to Buy from Neutral at Nomura Instinet by analyst Jeffrey Kvaal to reflect the webscale uptick and believes tax reform and the company's recurring revenue transition provide downside protection. Kvaal believes the recent pullback in Cisco shares provides a buying opportunity. 4. Tallgrass Energy Partners (TEP) upgraded to Overweight from Equal Weight at Barclays by analyst Christine Cho, who lowered her price target to $43 from $50. The analyst said her analysis suggests a Tallgrass Energy GP (TEGP) acquisition of Tallgrass Energy Partners is the most likely scenario. She valued Tallgrass Energy Partner at $43 in this scenario. 5. VF Corp (VFC) upgraded to Buy from hold at Stifel by analyst Jim Duffy, who sees fiscal 2019 consensus estimates rising throughout the year due to fundamental strength, environmental factors, and currency. Duffy believes VF shares can sustain the premium multiple for the "foreseeable future." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/18
FBCO
02/12/18
UPGRADE
Target $23
FBCO
Outperform
Credit Suisse upgrades Teva to Outperform amid execution on restructuring
Credit Suisse analyst Vamil Divan upgraded Teva Pharmaceutical to Outperform from Neutral and raised his price target for the shares to $23 from $20. The analyst sees "early execution" towards the company's restructuring plan and believes its 2018 outlook is achievable. He feels expectations are now reasonable believes the upside path is now clearer.
02/11/18
FBCO
02/11/18
UPGRADE
FBCO
Outperform
Teva upgraded to Outperform from Neutral at Credit Suisse
BRK.A Berkshire Hathaway
$302,750.00

1745 (0.58%)

01/31/18
BERN
01/31/18
NO CHANGE
BERN
Bernstein not expecting Amazon/JPMorgan/Berkshire coalition to become insurer
Bernstein analyst Lance Wilkes notes that Amazon (AMZN), JPMorgan (JPM) and Berkshire Hathaway (BRK.A; BRK.B) announced a plan to partner to offer healthcare services to their employees. The analyst does not expect this coalition or new company to become a health insurer, or to create meaningful disruption in core functions of the MCO. Wilkes thinks these three companies will create a new company that will focus on address four high impact areas of healthcare, namely shift to value based care, pharmacy costs, keeping people health/population health management, and consumer engagement. While he believes the retail pharmacy effort of Amazon would not be housed in this coalition, Wilkes argues that this new company may contract with a to-be-developed Amazon online pharmacy.
02/05/18
BERN
02/05/18
NO CHANGE
BERN
More pronounced risks to drug supply chain from Amazon coalition, says Bernstein
Bernstein analyst Lance Wilkes thinks the risks to the drug supply chain from Amazon (AMZN), JPMorgan (JPM) and Berkshire Hathaway (BRK.A; BRK.B) healthcare joint venture are much more pronounced than risks to traditional MCOs. The analyst thinks the coalition could acquire a transparency PBM, effectively creating an employer PBM Co-op.
01/31/18
CHLM
01/31/18
NO CHANGE
CHLM
Amazon consortium could be longer-term health care disruptor, says Craig-Hallum
Craig-Hallum analyst Kevin Ellich says that Amazon (AMZN), Berkshire Hathaway (BRK.A; BRK.B), and JPMorgan (JPM) new company focused initially on technology solutions to provide simplified, high-quality, and transparent healthcare for their employees and families at a reasonable cost could be a longer-term health care disruptor but it may a little premature to jump to conclusions.
01/31/18
FBCO
01/31/18
NO CHANGE
FBCO
No impact on pharma/biotech from Amazon/JPM/Berkshire coalition, says Credit Suisse
Commenting on the news that Amazon (AMZN), JPMorgan (JPM) and Berkshire Hathaway (BRK.A; BRK.B) are partnering to offer healthcare services to their employees, Credit Suisse analyst Vamil Divan says he does not anticipate any impact on the pharmaceutical or biotechnology sectors in the near or immediate term. However, he acknowledged that the biopharma pricing and distribution models include some perverse incentives that could be ripe for potential disruption.
AMAG Amag Pharmaceuticals
$13.90

0.2 (1.46%)

12/07/17
12/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sogou (SOGO) initiated with an Overweight at JPMorgan. 2. Amag Pharmaceuticals (AMAG) initiated with a Neutral at B. Riley FBR. 3. Akebia (AKBA) initiated with a Buy at BTIG. 4. Synnex (SNX) initiated with a Buy at SunTrust. 5. Cancer Genetics (CGIX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/05/18
PIPR
02/05/18
NO CHANGE
Target $15
PIPR
Neutral
Amag label doubles total addressable market, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says FDA approval of broad label use for Amag Pharmaceuticals' Feraheme in eligible adult patients with iron deficiency anemia doubles the company's total addressable market. The analyst, however, already models for this as the news was expected. Company data values the iron deficiency anemia market at $390M, or the same size as the CKD-related iron deficiency market, Raymond tells investors in a research note. He keeps a Neutral rating on Amag with a $15 price target.
02/15/18
JANY
02/15/18
UPGRADE
JANY
Buy
Amag Pharmaceuticals upgraded to Buy from Neutral at Janney Capital
02/15/18
COWN
02/15/18
NO CHANGE
Target $20
COWN
Market Perform
Cowen drops Amag target to $20 despite good start to 2018
Cowen analyst Ken Cacciatore says Amag Pharmaceuticals has had a nice start to 2018, with the Makena autoinjector approval "now part of the recovery." While encouraged by recent developments, the analyst remains focused on the Intrarosa launch and any potential generics of Makena. He sees a number a "similarly positioned inexpensive companies, but with a better collection of assets." As such, Cacciatore keeps a Market Perform rating on Amag. He dropped his price target for the shares to $20 from $22.
ATRS Antares Pharma
$1.98

-0.03 (-1.49%)

10/23/17
MSCO
10/23/17
NO CHANGE
Target $26
MSCO
Overweight
Antares CRL should have limited read through to Amag, says Morgan Stanley
After Antares Pharma (ATRS) announced that it has received a FDA complete response letter about the new drug application for Xyosted due to two deficiencies related to clinical data, Morgan Stanley analyst Thomas Smith said the CRL should have limited read through to Amag Pharmaceuticals (AMAG), which has partnered with Antares for technology being used in subcutaneous Makena. The CRL is not related to the device or manufacturing, noted Smith, who adds that investor relief over the minimal Makena read through could lead to a rally in Amag shares following the recent weakness. He keeps 60% probability of success for Makena SC and maintains an Overweight rating on Amag shares.
10/23/17
PIPR
10/23/17
NO CHANGE
Target $3
PIPR
Overweight
Antares shares 'can and should' recover, says Piper Jaffray
Piper Jaffray analyst David Amsellem believes shares of Antares Pharma "can and should" recover following the complete response letter from the FDA regarding its new drug application for Xyosted. The letter is a major delay and calls into question if the product will ever reach commercialization, Amsellem tells investors in a research note. The analyst, however, highlights the company's "myriad other value drivers," namely a potential AB-rated generic form of EpiPen. He lowered his price target for Antares shares to $3 from $4 and reiterates an Overweight rating on the name.
10/23/17
RAJA
10/23/17
NO CHANGE
Target $3.4
RAJA
Strong Buy
Antares Pharma maintained as a Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur said the FDA's CRL on Antares Pharma (ATRS) XYOSTED was an unexpected and significant setback, but weakness in shares since the October disclosure effectively prices XYOSTED at zero, and substantially undervalues other development programs, especially ANDA products with Teva (TEVA). Wilbur is not writing-off XYSTED yet and is pushing out an expected launch to 2H19 from early 2018 previously, and is now discounting the probability of success at 50% versus 100% prior to the CRL. The analyst maintains asset values for Antares' non-XYOSTED assets are worth $2.50 per share using a sum-of-the-parts valuation and adjusted his price target to $3.40 from $4.20 on shares. Wilbur maintains a Strong Buy rating on Antares
10/23/17
JANY
10/23/17
NO CHANGE
JANY
Neutral
Antares CRL doesn't raise issues for Amag Pharmaceuticals, says Janney Capital
Janney Capital analyst Ken Trbovich noted that the FDA complete response letter issued to Antares (ATRS) for Xyosted did not pertain to the Quickshot subcutaneous autoinjector, which raises his confidence the FDA will not identify such issues as a short coming of the sNDA for Amag Pharmaceuticals' (AMAG) Makena SQ. However, he keeps a Neutral rating on Amag shares, noting that the primary uncertainty for the sNDA for Makena SQ is the fact that its peak plasma levels is higher than the upper bound the FDA uses to define bioequivalence.
SEDG SolarEdge
$36.90

0.9 (2.50%)

02/15/18
OPCO
02/15/18
NO CHANGE
Target $50
OPCO
Outperform
SolarEdge price target raised to $50 from $38 at Oppenheimer
Oppenheimer analyst Colin Rusch raised his price target for SolarEdge to $50 from $38 after Q4 results beat expectations and the company guided Q1 above consensus estimates. The analyst reiterates an Outperform rating on the shares.
02/15/18
ROTH
02/15/18
NO CHANGE
Target $60
ROTH
Buy
SolarEdge price target raised to $60 from $42 at Roth Capital
Roth Capital analyst Philip Shen raised his price target for SolarEdge to $60 from $42 after a "strong" Q4 beat and Q1 guide, and as he sees more upside from here. The analyst reiterates a Buy rating on the shares.
02/15/18
COWN
02/15/18
NO CHANGE
Target $53
COWN
Outperform
SolarEdge price target raised to $53 from $41 at Cowen
Cowen analyst Jeffrey Osborne raised his price target on SolarEdge to $53 from $41 following its "blowout" Q4 results and "solid" Q1 guidance. The analyst cited its market share gains, gross margins, and plans for cost reductions. Osborne reiterated his Outperform rating on SolarEdge shares.
02/15/18
JPMS
02/15/18
NO CHANGE
Target $52
JPMS
Overweight
SolarEdge price target raised to $52 from $43 at JPMorgan
JPMorgan analyst Mark Strouse raised his price target for SolarEdge Technologies to $52 saying the company's Q4 results included record highs for revenue, gross margin, earnings and operating cash flow, with the Q1 guidance pointing to further growth. SolarEdge's momentum remains solid, despite "moribund growth" in the U.S. residential market, owing to market share gains and international growth, Strouse tells investors in a post-earnings research note. He keeps an Overweight rating on the shares.
TRIP TripAdvisor
$40.72

0.84 (2.11%)

01/02/18
BOFA
01/02/18
NO CHANGE
BOFA
BofA/Merrill's Top 10 US Ideas for Q1 2018
BofA/Merrill named its Top 10 Ideas for Q1 2018. They are Buy rated AMD (AMD), Disney (DIS), Exact Sciences (EXAS), Exelon (EXC), lululemon (LULU), PayPal (PYPL), United Rentals (URI), and Walmart (WMT), and Underperform rated L Brands (LB) and TripAdvisor (TRIP).
02/15/18
PIPR
02/15/18
NO CHANGE
Target $47
PIPR
Neutral
TripAdvisor price target raised to $47 from $40 at Piper Jaffray
Piper Jaffray analyst Michael Olson raised his price target for TripAdvisor to $47 saying the company last night reported "strong" results with revenue and EBITDA above consensus. TripAdvisor guided to flat year-over-year EBITDA, which is favorable when compared to consensus at down 5.5%, Olson tells investors in a post-earnings research note. He maintains a Neutral rating on the shares.
01/05/18
SBSH
01/05/18
NO CHANGE
Target $1400
SBSH
Buy
Citi names Amazon top Internet pick for 2018, ups target to $1,400
Citi analyst Mark May remains bullish on the consumer Internet sector, especially over the near term. The analyst believes a "positive, tax reform fueled, business climate" should benefit the end-markets of the companies in the space. After outperformance in 2017, however, he recommends being more selective in 2018. Amazon.com (AMZN) moves up a spot to become his top-ranked pick for 2018. May sees the combination of greater than 30% sales growth, margin expansion and the current valuation as a "compelling mix." He raised his price target for Amazon shares to $1,400 from $1,250. May's most- to least-favored stocks under coverage, in order, are: Amazon, Expedia (EXPE), Facebook (FB), Priceline (PCLN), Alphabet (GOOGL), eBay (EBAY), Yelp (YELP), Twitter (TWTR), TripAdvisor (TRIP), Netflix (NFLX), GrubHub (GRUB), GoDaddy (GDDY), Despegar.com (DESP), trivago (TRVG), LendingClub (LC), Wayfair (W), Snap (SNAP), Zillow (ZG), Blue Apron (APRN) and Roku (ROKU), which he downgraded this morning to Sell.
02/15/18
JEFF
02/15/18
NO CHANGE
Target $27
JEFF
Underperform
TripAdvisor core business is declining, valuation looks rich, says Jefferies
In a post-earnings research note titled "Stay Clear of This Trip," Jefferies analyst Brent Thill says TripAdvisor last night reported a mixed quarter with revenue and adjusted EBITDA above consensus and operating earnings short of expectations on higher taxes. The analyst sees "much better alternatives" among the online travel agencies with TripAdvisor's core business declining and its stock trading at 15 times 2018 EBITDA estimates. Thill says the valuation "looks rich" and keeps an Underperform rating on TripAdvisor with a $27 price target.
AAN Aaron's
$46.31

5.98 (14.83%)

11/29/17
SIDC
11/29/17
UPGRADE
Target $45
SIDC
Buy
Aaron's upgraded to Buy from Neutral at Sidoti
Sidoti analyst Brian Hollenden upgraded Aaron's to Buy saying the recent pullback in shares provides meaningful upside to his $45 price target.
01/24/18
LOOP
01/24/18
DOWNGRADE
Target $42
LOOP
Hold
Aaron's downgraded to Hold from Buy at Loop Capital
Loop Capital analyst Anthony Chukumba downgraded Aaron's to Hold from Buy while keeping his $42 price target. Chukumba says the downgrade is based on valuation rather than fundamentals, forecasting the company's core business to improve sequentially and also see benefits from the U.S. tax changes. The analyst notes that after a recent run-up in the stock price, the current valuation is in line with his "relatively bullish fundamental outlook".
01/24/18
01/24/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. United Continental (UAL) downgraded to In Line from Outperform at Evercore ISI with analyst Duane Pfennigwerth citing the company's investor update. 2. Huntington Bancshares (HBAN) was downgraded to Neutral from Buy at Hilliard Lyons and to Neutral from Outperform at Macquarie. 3. Range Resources (RRC) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Evan Calio saying he expects oil markets to tighten and gas to remain weak in 2018. 4. CEVA downgraded to Perform from Outperform at Oppenheimer with analyst Andrew Uerkwitz downgraded Ceva (CEVA) to Perform from Outperform saying the valuation looks "full" at current levels. 5. Aaron's (AAN) downgraded to Hold from Buy at Loop Capital with analyst Anthony Chukumba citing valuation rather than fundamentals, forecasting the company's core business to improve sequentially and also see benefits from the U.S. tax changes. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/01/17
NRCS
12/01/17
NO CHANGE
Target $52.5
NRCS
Buy
Aaron's working to leverage Amazon traffic and mindshare, says Northcoast
Northcoast analyst Nick Mitchell said channel work indicates Aaron's (AAN) Progressive segment is working diligently to put together a scalable go-to-market strategy that would allow it to leverage Amazon's (AMZN) traffic and mindshare. The analyst believes Progressive's market leading position will translate into significant growth over the next 5 to 10 years and thinks Amazon could conservatively represent a $240M to $721M inventory outsourcing opportunity, or operating income in the range of $45M to $218M. Mitchell views this as another good reason to own the stock at these levels and reiterates his Buy rating and $52.50 price target on Aaron's.
AA Alcoa
$46.95

-1.59 (-3.28%)

12/20/17
FBCO
12/20/17
UPGRADE
Target $61
FBCO
Outperform
Credit Suisse upgrades Alcoa ahead of aluminum market tightening
Credit Suisse analyst Curt Woodworth upgraded Alcoa to Outperform from Neutral and raised his price target for the shares to $61 from $42. The aluminum market is set to tighten into 2018, as structural policies in China address captive coal plants and illegal smelters remain intact, Woodworth tells investors in a research note. The analyst sees downstream demand "sharply" recovering in Q1 of 2018 and views Alcoa's valuation as compelling at current levels. The company is set to become a capital return story with $525M of potential capital to be returned in 2018 via dividends or buybacks, Woodworth contends. Further, the analyst thinks Alcoa could be added to the S&P 500 index in 2018.
01/11/18
SBSH
01/11/18
NO CHANGE
Target $65
SBSH
Buy
Alcoa price target raised to $65 from $53 at Citi
Citi analyst Alexander Hacking raised his price target for Alcoa to $65 on the belief that "sustainably higher" aluminum prices, supported by the cost curve, will re-rate multiples higher. The analyst believes the stock looks inexpensive and he keeps a Buy rating on the shares.
01/18/18
BOFA
01/18/18
NO CHANGE
Target $63
BOFA
Buy
Alcoa price target lowered to $63 from $67 at BofA/Merrill
BofA/Merrill analyst Timna Tanners lowered her price target for Alcoa to $63 from $67 following quarterly results. While the company reported above consensus 2018E EBITDA outlook, cost pressures dampened enthusiasm, the analyst notes. Nonetheless, Tanners reiterates a Buy rating on the shares given her above guidance EBITDA forecasts on a positive view on aluminum, and as she believes cash return to shareholders likely in H2 is a positive catalyst.
01/18/18
JPMS
01/18/18
NO CHANGE
Target $68
JPMS
Overweight
Alcoa price target raised to $68 from $55 at JPMorgan
JPMorgan analyst Michael Gambardella raised his price target for Alcoa to $68 following the company's Q4 results to reflect higher alumina and aluminum prices. The analyst notes, however, that higher raw material costs are acting as a partial offset. Alumina and aluminum prices will be supported by capacity cuts in China and Alcoa has "significant leverage" to these prices given its attractive cost structure, Gambardella tells investors in a post-earnings research note. He also thinks the stock could benefit from Alcoa potentially being added to the S&P 500 in the next few months. The analyst keeps an Overweight rating on the shares.
THS TreeHouse
$37.04

-5.97 (-13.88%)

01/04/18
WELS
01/04/18
NO CHANGE
Target $46
WELS
Market Perform
TreeHouse price target raised to $46 from $41 at Wells Fargo
Wells Fargo analyst John Baumgartner raised his price target for TreeHouse to $46 from $41, citing tax reform and stronger macros. The analyst reiterates a Market Perform rating on the shares.
12/13/17
JPMS
12/13/17
NO CHANGE
Target $39
JPMS
Underweight
JPMorgan 'increasingly pessimistic' on TreeHouse's cash flow outlook
JPMorgan analyst Joshua Levine says he's "increasingly pessimistic" about the near-term free cash flow outlook for TreeHouse Foods. The analyst sees a "number of quantifiable drivers" that could cause the company's free cash flow to come in meaningfully below consensus in 2018 and 2019. He sees another potential leg down for the stock and keeps an Underweight rating on TreeHouse with a $39 price target.
11/16/17
VERF
11/16/17
UPGRADE
VERF
Buy
TreeHouse upgraded to Buy from Hold at Vertical Group
12/04/17
WOLF
12/04/17
INITIATION
WOLF
Peer Perform
TreeHouse initiated with a Peer Perform at Wolfe Research
NTAP NetApp
$60.64

1.9 (3.23%)

02/15/18
LSCM
02/15/18
NO CHANGE
Target $62
LSCM
Buy
NetApp price target raised to $62 from $54 at Lake Street
Lake Street analyst Eric Martinuzzi raised his price target for NetApp to $62 saying double-digit product growth drove another good quarter. The analyst keeps a Buy rating on the shares.
02/15/18
WELS
02/15/18
NO CHANGE
Target $62
WELS
Market Perform
NetApp price target raised to $62 from $54 at Wells Fargo
Wells Fargo analyst Aaron Rakers raised his price target for NetApp to $62 from $54 following "strong" results. The analyst reiterates a Market Perform rating on the shares.
02/15/18
BOFA
02/15/18
NO CHANGE
Target $74
BOFA
Buy
NetApp weakness a buying opportunity, says BofA/Merrill
BofA/Merrill analyst Wamsi Mohan said NetApp's Q3 delivered a slight beat and Q4 guidance implies positive revenue trends will continue but with a higher product mix that is negative for gross margins. Mohan views the quarter-over-quarter product gross margin decline as seasonal, not structural, and believes the company can deliver 50%+ product gross margin, and expects an increase to the dividend and a material increase in buybacks at the April Analyst Day. The analyst reiterates a Buy rating and $74 price target and recommends using weakness as a buying opportunity.
02/15/18
LOOP
02/15/18
NO CHANGE
Target $69
LOOP
Buy
Recommend accumulating NetApp on weakness, says Loop Capital
Loop Capital analyst Ananda Baruah kept his Buy rating and $69 price target on NetApp after the company's latest results, but says he would be a "strong accumulator" of the stock on weakness. The analyst notes that the earnings and the guidance for next quarter add to his confidence and suggest that a material expansion remains ahead, given that the Q4 outlook is likely conservative based on the implied Strategic revenue view and accelerating adoption momentum.
MRO Marathon Oil
$15.75

-1.2 (-7.08%)

01/30/18
WOLF
01/30/18
DOWNGRADE
WOLF
Peer Perform
Marathon Oil downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Marathon Oil to Peer Perform citing valuation.
01/17/18
JPMS
01/17/18
NO CHANGE
Target $20
JPMS
Neutral
Marathon Oil price target raised to $20 from $15 at JPMorgan
JPMorgan analyst Arun Jayaram believes the near-term risk/reward for shares of Marathon Oil is favorable. The analyst keeps a Neutral rating on the name but raised his price target for the shares to $20 from $15. Jayaram sees upside to consensus production estimates owing to well productivity gains observed in the Williston Basin and Eagle Ford Shale.
01/04/18
BOFA
01/04/18
UPGRADE
Target $21
BOFA
Buy
Marathon Oil upgraded to Buy at BofA/Merrill
As previously reported, BofA/Merrill upgraded Marathon Oil to Buy from Neutral and increased its price target to $21 from $18. Analyst Doug Leggate believes Marathon is entering a period of "beat and raise" in terms of well economics and resource backlog in the Bakken, and said it has one of the strongest balance sheets among peers.
01/04/18
BOFA
01/04/18
UPGRADE
BOFA
Buy
Marathon Oil upgraded to Buy from Neutral at BofA/Merrill

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

11:16
02/23/18
02/23
11:16
02/23/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$68.93

0.47 (0.69%)

11:12
02/23/18
02/23
11:12
02/23/18
11:12
Conference/Events
Xilinx management to meet with KeyBanc »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

HMHC

Houghton Mifflin

$7.65

0.1 (1.32%)

11:10
02/23/18
02/23
11:10
02/23/18
11:10
Options
Hefty option block in Houghton Mifflin Harcourt as shares falter »

Hefty option block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRA

Kraton

$45.31

1.6 (3.66%)

11:10
02/23/18
02/23
11:10
02/23/18
11:10
Conference/Events
Kraton management to meet with KeyBanc »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SBUX

Starbucks

$55.40

-0.7 (-1.25%)

11:00
02/23/18
02/23
11:00
02/23/18
11:00
Options
Starbucks puts active at the opening bell Friday »

Starbucks puts active at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 21

    Mar

PSO

Pearson

$9.66

-0.08 (-0.82%)

10:50
02/23/18
02/23
10:50
02/23/18
10:50
Hot Stocks
Pearson sees FY18 adjusted ops profit GBP520M-GBP560M »

The base for 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$96.83

-0.06 (-0.06%)

10:50
02/23/18
02/23
10:50
02/23/18
10:50
Options
25K Lowes Mar - Oct 95 call spreads bought for $5.75 »

25K Lowes Mar - Oct 95…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 07

    Mar

PSO

Pearson

$9.66

-0.08 (-0.82%)

10:48
02/23/18
02/23
10:48
02/23/18
10:48
Earnings
Pearson reports preliminary FY17 adjusted operating profit GBP576M, down 9% »

Reports preliminary FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKX

Skechers

$39.04

0.8299 (2.17%)

10:45
02/23/18
02/23
10:45
02/23/18
10:45
Options
Skechers call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

10:45
02/23/18
02/23
10:45
02/23/18
10:45
General news
Boston Fed hawk Rosengren: low real rates are likely for some time »

Boston Fed hawk…

MDT

Medtronic

$80.51

0.1 (0.12%)

10:45
02/23/18
02/23
10:45
02/23/18
10:45
Conference/Events
Medtronic has a conference call hosted by JPMorgan »

JPMorgan Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 14

    Mar

  • 23

    Mar

TTMI

TTM Technologies

$15.52

-0.07 (-0.45%)

10:45
02/23/18
02/23
10:45
02/23/18
10:45
Conference/Events
TTM Technologies has a conference call hosted by JPMorgan »

JPMorgan Analyst Coster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

VLKAY

Volkswagen

$40.89

0.46 (1.14%)

10:41
02/23/18
02/23
10:41
02/23/18
10:41
Earnings
Volkswagen sees fiscal 2018 sales up as much as 5% »

Volkswagen said in its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$38.15

-0.2 (-0.52%)

, FOXA

21st Century Fox

$37.16

0.1 (0.27%)

10:39
02/23/18
02/23
10:39
02/23/18
10:39
Hot Stocks
Box Office Battle: 'Black Panther' expecting $120M second weekend »

Marvel and Disney's…

VIA

Viacom

$38.15

-0.2 (-0.52%)

FOXA

21st Century Fox

$37.16

0.1 (0.27%)

LGF.B

Lionsgate

$26.79

0.01 (0.04%)

VIAB

Viacom

$32.93

-0.1 (-0.30%)

CMCSA

Comcast

$38.80

-0.21 (-0.54%)

CMCSK

Comcast

LGF.A

Lionsgate

$28.02

0.05 (0.18%)

TWX

Time Warner

$94.17

-0.2 (-0.21%)

DIS

Disney

$105.53

0.29 (0.28%)

SNE

Sony

$49.64

-0.21 (-0.42%)

FOX

21st Century Fox

$36.73

0.17 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 01

    Mar

  • 05

    Mar

  • 20

    Mar

  • 23

    Apr

10:35
02/23/18
02/23
10:35
02/23/18
10:35
General news
FX Action: USD-CAD »

FX Action: USD-CAD slid…

ATI

Allegheny Technologies

$27.04

0.41 (1.54%)

10:33
02/23/18
02/23
10:33
02/23/18
10:33
Conference/Events
Allegheny Technologies management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 01

    May

  • 02

    May

  • 03

    May

NVRO

Nevro

$81.92

2.27 (2.85%)

10:31
02/23/18
02/23
10:31
02/23/18
10:31
Recommendations
Nevro analyst commentary  »

Nevro setup favorable,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
02/23/18
02/23
10:30
02/23/18
10:30
General news
Treasury Option Action: put buying in the belly »

Treasury Option Action:…

10:27
02/23/18
02/23
10:27
02/23/18
10:27
Conference/Events
Leerink healthcare analysts to hold an analyst/industry conference call »

Analysts provide a…

MDXG

MiMedx

$8.88

-0.17 (-1.88%)

10:25
02/23/18
02/23
10:25
02/23/18
10:25
Conference/Events
MiMedx to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 14

    Mar

10:24
02/23/18
02/23
10:24
02/23/18
10:24
General news
Averages up in early trading but off best levels »

Stock futures moved…

WRK

WestRock

$65.72

0.44 (0.67%)

10:21
02/23/18
02/23
10:21
02/23/18
10:21
Conference/Events
WestRock management to meet with Buckingham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

GILD

Gilead

$79.40

-1.29 (-1.60%)

, GSK

GlaxoSmithKline

$36.67

0.1 (0.27%)

10:20
02/23/18
02/23
10:20
02/23/18
10:20
Conference/Events
Leerink pharmaceuticals analysts to hold an analyst/industry conference call »

Analyst Research Team…

GILD

Gilead

$79.40

-1.29 (-1.60%)

GSK

GlaxoSmithKline

$36.67

0.1 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 25

    Mar

  • 23

    Apr

A

Agilent

$70.76

0.08 (0.11%)

10:20
02/23/18
02/23
10:20
02/23/18
10:20
Options
$5.6M put buyer in Agilent »

$5.6M put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

VLKAY

Volkswagen

$40.89

0.46 (1.14%)

10:19
02/23/18
02/23
10:19
02/23/18
10:19
Earnings
Volkswagen reports year adjusted operating profit EUR 17B, consensus EUR 17.29B »

Reports year revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.